Provided by Tiger Trade Technology Pte. Ltd.

Vera Therapeutics, Inc.

32.29
-1.0900-3.27%
Post-market: 32.500.2100+0.65%17:57 EDT
Volume:1.52M
Turnover:48.83M
Market Cap:2.32B
PE:-5.79
High:34.06
Open:33.38
Low:31.40
Close:33.38
52wk High:56.05
52wk Low:19.07
Shares:71.71M
Float Shares:50.20M
Volume Ratio:0.99
T/O Rate:3.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.5746
EPS(LYR):-4.6644
ROE:-71.32%
ROA:-38.90%
PB:4.63
PE(LYR):-6.92

Loading ...

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 06

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 06

Analysts’ Top Healthcare Picks: Vera Therapeutics (VERA), Johnson & Johnson (JNJ)

TIPRANKS
·
Jun 06

Vera Therapeutics posts atacicept IgA nephropathy trial presentation

Reuters
·
Jun 05

Otsuka says kidney disease drug preserves function in late-stage study

Reuters
·
Jun 05

Analysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), OrthoPediatrics (KIDS)

TIPRANKS
·
Jun 03

Vera Therapeutics Aligns With FDA on Earlier Atacicept Analysis to Support Potential Full Approval

MT Newswires Live
·
Jun 03

Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis

TIPRANKS
·
Jun 03

Raymond James sees unique buying opportunity in Vera after FDA alignment

TIPRANKS
·
Jun 03

BUZZ-U.S. STOCKS ON THE MOVE-Dollar General, Vera, Amtech Systems

Reuters
·
Jun 02

Vera Therapeutics: Buy Rating Reiterated as Atacicept’s Regulatory Path Advances; $90 Price Target Maintained

TIPRANKS
·
Jun 02

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), Vera Therapeutics (VERA) and Regeneron (REGN)

TIPRANKS
·
Jun 02

Vera Therapeutics Advances Atacicept Approval Path in IgA Nephropathy

TIPRANKS
·
Jun 02

BUZZ-Vera rises as FDA agrees to review late-stage kidney drug data for full approval

Reuters
·
Jun 02

Vera Therapeutics pulls forward ORIGIN phase 3 eGFR analysis of atacicept in IgA nephropathy to Q3 2026

Reuters
·
Jun 02

Vera Therapeutics, - Revised Origin 3 Egfr Analysis Planned for Q3 2026

THOMSON REUTERS
·
Jun 02

Vera Therapeutics Announces Alignment With U.S. FDA on Earlier Origin Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults With Iga Nephropathy

THOMSON REUTERS
·
Jun 02

Vera Therapeutics, - Pdufa Date Set for July 7, 2026 for Atacicept in Igan

THOMSON REUTERS
·
Jun 02

Vera Therapeutics, - Plans to Submit Sbla in Q4 2026 for Potential Full Approval in 2027

THOMSON REUTERS
·
Jun 02

Vera Therapeutics shareholders elect Class II directors at annual meeting

Reuters
·
May 27